Report calls for $2bn global fund to kickstart antibiotic developmentBMJ 2015; 350 doi: https://doi.org/10.1136/bmj.h2635 (Published 14 May 2015) Cite this as: BMJ 2015;350:h2635
- Jacqui Wise
A review on antimicrobial resistance commissioned by the UK prime minister has called for the establishment of a global innovation fund of around $2bn over five years to boost funding for “blue sky” research into drugs and diagnostics.
Its report said that there was a need to kickstart drug development to tackle the growing global problem of drug resistant infections.1 This was the economist Jim O’Neill’s third paper on the challenges of antimicrobial resistance.2
Another recommendation is for a global organisation to make lump sum payments to drug companies to incentivise the development of the most needed antibiotics. Payment would be set against selective criteria agreed in advance. The report said that this approach would “de-link” the profitability of a drug from volume of sales. It would get rid of the commercial imperative for drug companies to sell large quantities of new antibiotics, which had contributed to the spread of resistance.
The report, which David Cameron commissioned in July 2014, also called for innovative partnerships between academia …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial